Skip to main content

Table 2 Secondary efficacy outcomes

From: Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

EDSSPlacebo N = 17AP N = 20p
Baseline median EDSS6.0 (2.5–7.0)6.0 (3.5–7.5)0.92
Final median EDSS6.5 (2.0–8.0)6.0 (3.0–7.5)0.24
Baseline mean EDSS5.7 ± 1.35.8 ± 1.10.93
Final mean EDSS6.2 ± 1.35.8 ± 1.30.43
Mean EDSS change+ 0.35 (95% CI, −0.75 - 0.05)−0.03 (95% CI, − 0.4 - 0.4)0.04a
Other efficacy outcomesPlaceboN = 17APN = 20p
mean change (95% CI)mean change (95% CI)
SDMT0.49 (0.05–0.92)0.23 (−0.13–0.59)0.36
PASAT0.28 (−0.57–1.09)0.22 (− 0.44–0.89)0.92
9HPT0.01 (−2.18–2.16)−1.55 (−3.65–0.54)0.32
T25FW1.58 (−5.39–8.56)−1.19 (−7.15–4.77)0.56
MSFC0.05 (−0.19–0.29)0.11 (− 0.62–0.29)0.69
RNFL−9.2 (− 12.9–5.5)−7.3 (− 11.2–3.3)0.47
  1. aAdjusted model (baseline EDSS as a covariate); the mean difference between AP and placebo was 0.63
  2. SMDT: symbol digit modalities test; PASAT Paced auditory serial addition test; 9HPT Nine-hole peg test; T25FW Timed 25-ft walk; MSFC Multiple sclerosis functional composite; RNFL Retinal nerve fibre layer. The results from GLM were adjusted for baseline MSFC